Recherche avancée
Affichage des résultats 8221 à 8240 sur 8426 au total
-
[Does aspirin have a place in primary cardiovascular prevention by the polypill ? Simulation study on a realistic virtual population].
Mor Fall, Guillaume Grenet, Hai-Ha Le, Behrouz Kassaï, Jean-Christophe Lega, Rémy Boussageon, Sabine Mainbourg, Ivanny Marchant, Johanne Gafsi, Amadou Moctar Dieye, François Gueyffier
-
Implementation of a centralized pharmacovigilance system in academic pan‐European clinical trials: Experience from EU‐Response and conect4children consortia
Catherine Cornu, Anne Donche, Carine Coffre, Amélie Le Gouge, Boulkedid Rym, Isabelle Vaugier, Frédéric Barbot, Alain Leizorovicz, Nadine Juge, Céline Giraud, François Gueyffier, Alexandra Félin, Thibault Mura, Hugues Chevassus, Christine Binquet
-
Pharmacokinetic/pharmacodynamic model of a methionine starvation based anti-cancer drug
N. Eymard, N. Bessonov, V. Volpert, P. Kurbatova, F. Gueyffier, P. Nony
-
Projet Rebuild the Evidence Base
Hélène Vaillant-Roussel, Clara Blanchard, Thibault Menini, Elodie Charuel, Bruno Pereira, Florian Naudet, Behrouz Kassai Koupai, Guillaume Grenet, François Gueyffier, Michel Cucherat, Rémy Boussageon
-
Association between difference in blood pressure reduction and risk of cardiovascular events in a type 2 diabetes population: A meta-regression analysis
G. Grenet, H. H. Le, T. Bejan-Angoulvant, S. Erpeldinger, R. Boussageon, B. Kassai, P. Moulin, F. Gueyffier, M. Cucherat
-
GLUcose COntrol Safety & Efficacy in type 2 DIabetes, a systematic review and NETwork meta-analysis
G. Grenet, S. Ribault, G. B. Nguyen, F. Glais, A. Metge, T. Linet, B. Kassai-Koupai, C. Cornu, T. Bejan-Angoulvant, S. Erpeldinger, R. Boussageon, A. Gouraud, F. Bonnet, M. Cucherat, P. Moulin, F. Gueyffier
-
Efficacy and safety of insulin in type 2 diabetes: meta-analysis of randomised controlled trials
S. Erpeldinger, M. B. Rehman, C. Berkhout, C. Pigache, Y. Zerbib, F. Regnault, E. Guerin, I. Supper, Catherine Cornu, B. Kassai, F. Gueyffier, R. Boussageon
-
Can we identify response markers to antihypertensive drugs? First results from the Ideal Trial
F. Gueyffier, F. Subtil, T. Bejan-Angoulvant, Y. Zerbib, J. P. Baguet, J. M. Boivin, A. Mercier, G. Leftheriotis, J. P. Gagnol, J. P. Fauvel, C. Giraud, G. Bricca, Delphine Maucort-Boulch, S. Erpeldinger
-
Different treatment benefits were estimated by clinical trials performed in adults compared with those performed in children
Perrine Janiaud, A. Lajoinie, F. Cour-Andlauer, Catherine Cornu, P. Cochat, Michel Cucherat, F. Gueyffier, B. Kassai
-
The effect of methylphenidate on neurofibromatosis type 1: a randomised, double-blind, placebo-controlled, crossover trial
Laurence Lion-François, François Gueyffier, Catherine Mercier, Daniel Gérard, Vania Herbillon, Isabelle Kemlin, Diana Rodriguez, Tiphanie Ginhoux, Emeline Peyric, Virginie Coutinho, Valentine Bréant, Vincent Des Portes, Stéphane Pinson, Patrick Combemale, Behrouz Kassai
-
Essais cliniques institutionnels : quel monitoring ?
C. Cornu, C. Binquet, C. Thalamas, C. Vigouroux, S. Gaillard, T. Ginhoux, B. Vaz, C. Jossan, A. Félin, A. Sailly, François Gueyffier, V. Journot, Behrouz Kassai
-
Are concomitant treatments confounding factors in randomized controlled trials on intensive blood-glucose control in type 2 diabetes? a systematic review
Rémy Boussageon, Irène Supper, Sylvie Erpeldinger, Michel Cucherat, Theodora Bejan-Angoulvant, Behrouz Kassai, Catherine Cornu, François Gueyffier
-
L\textquoterighteffet placebo chez l\textquoterightenfant est méconnu et peu étudié
B. Kassai, H. Gheit, R. Boussageon, F. Gueyffier
-
Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials.
Rémy Boussageon, Irène Supper, Theodora Bejan-Angoulvant, Nadir Kellou, Michel Cucherat, Jean-Pierre Boissel, Behrouz Kassai, Moreau Alain, François Gueyffier, Catherine Cornu
-
Effect of intensive glucose lowering treatment on all cause mortality cardiovascular death and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials
R. Boussageon, T. Bejan-Angoulvant, M. Saadatian-Elahi, S. Lafont, C. Bergeonneau, Behrouz Kassai, S. Erpeldinger, Jm. Wright, François Gueyffier, Catherine Cornu
-
SCORE should be preferred to Framingham to predict cardiovascular death in French population
I. Marchant, J-P. Boissel, Behrouz Kassai, T. Bejan-Angoulvant, J. Massol, C. Vidal, E. Amsallem, F. Naudin, P. Galan, S. Czernichow, Patrice Nony, François Gueyffier
-
Recueil systématique et actif des evènements indésirables médicamenteux chez les enfants admis aux urgences pédiatriques
F. Planchamp, K.-A. Nguyen, T. Vial, S. Nasri, E. Javouhey, Y. Gillet, B. Ranchin, F. Villard, D. Floret, P. Cochat, François Gueyffier, Behrouz Kassai
-
Severe myoclonic epilepsy in infancy: A systematic review and a meta-analysis of individual patient data
Behrouz Kassai, C. Chiron, S. Augier, Michel Cucherat, E. Rey, François Gueyffier, R. Guerrini, J. Vincent, O. Dulac, Gérard Pons
-
Critères intermédiaires et critères de substitution
Behrouz Kassai, François Gueyffier, J-P. Boissel
-
Safety of computerized drug management: a case report
K.-A. Nguyen, T. Vial, François Gueyffier, S. Marignier, P. Cochat, Behrouz Kassai